Skip to content
Sanatan Upmanyu

About.

I’m a data-science executive with 18+ years spanning wet-lab biology, AI/ML engineering, HPC/cloud infrastructure, and leadership across pharma, biotech, and consumer health.

I architected the AlphaMeld™ platform — an end-to-end AI stack that accelerates target triage and indication selection for global drug-makers. My work covers clinical-trial design and enrollment prediction, digital-twin modelling, and large-scale knowledge-graph analytics.

I care about converting multimodal data into real business value, scaling cross-site teams, and forging the kind of partnerships that redefine R&D.

Career

  1. Apxora GmbHnow
    Co-Founder & AI/Data Science Head · Basel, Switzerland
    Dec 2024 – Present
    PythonLLMsReactAWSNeo4j
    • — Co-founded the company and own the AI/data-science function end to end — technical strategy, architecture, hiring, and delivery across the product portfolio.
    • — Direct build and deployment of SequenceFlow ResearchNexus and Clinical Navigator: an integrated stack spanning knowledge graph, clinical-trial prediction, literature analysis, patient digital twins, TPP and TOP, with 12 ML models in production on PostgreSQL + Neo4j and self-hosted LLM APIs.
    • — Set the AI/ML agenda for early innovation-signal detection across emerging targets, novel therapeutics, and healthcare solutions — and translate it into the commercial product roadmap.
    • — Steer the Asset Lifecycle Manager and Portfolio Management platforms, extending the company's reach from discovery signals into portfolio decision-making.
    • — Lead delivery of AI engagements for top-tier global pharmaceutical companies (client names confidential).
  2. AlphaMeld GmbH (formerly InveniAI GmbH)now
    Head of Data Sciences — Site Head · Basel, Switzerland
    Dec 2020 – Present
    PythonNeo4jAWSReactLLMsKnowledge Graphs
    • — Site head for the Basel operation and owner of the data-sciences function — team of 5 data scientists, hiring, technical direction, and site-level delivery accountability.
    • — Own the AlphaMeld Operating System end to end — a custom UI layer (Knowledge Graph, ChatAlphaMeld, Bioinformatics, Literature Analysis, AlphaClinMeld) over 12 ML models — compressing hypothesis-to-insight cycles from months to weeks.
    • — Delivered AlphaCompass portfolio intelligence: adopted by two business-development teams within six months, standardizing evidence-based indication prioritization across 200 active programs.
    • — Directed the ChatAlphaMeld benchmark programme — 97.34% accuracy on a 188-question biomedical benchmark, outperforming leading general-purpose frontier models and delivering the step-by-step rationales complex clinical questions demand.
    • — Anchor platform delivery and support for the publicly announced collaborations that validate AlphaMeld commercially: Kyowa Kirin (multi-year strategic partnership; subscription-and-support relationship spanning five years, with an AI-identified program validated in preclinical proof-of-concept), Shionogi (multi-target drug discovery, worth up to $200M per program in upfronts, milestones, and royalties), GSK Consumer Healthcare (three-year AI innovation collaboration), and Ono Pharmaceutical (2024 target discovery).
    • — Act as senior data-science advisor to pharma and biotech clients, applying molecular-biology depth to MOA analysis and target-viability calls that shape client program decisions.
  3. ArtiXio Pvt Ltdnow
    Chief Technology Officer · Remote
    Sep 2017 – Present
    ReactNext.jsTypeScriptLLMsAgentic AIPostgreSQL
    • — Own technology strategy, architecture, and delivery for the company's entire digital product portfolio — concept to production — and the engineering function behind it.
    • — Conceptualized and built QuriousRI, a secure role-based regulatory-intelligence platform covering pharmaceuticals, biologics, biosimilars, and generics across 12+ agencies (FDA, EMA, PMDA, NMPA, Health Canada, MHRA, Swissmedic, and more).
    • — Extended QuriousRI into CTD dossier preparation, driving AI-assisted authoring across Modules 2 through 5 — and scoping Module 1 out deliberately, as country- and company-specific content that does not transfer reliably. Reproducibility tested and repeated to date on Module 2, the Quality Overall Summary, 3.2.P.1, and 3.2.P.3.3, with section coverage expanding.
    • — Built per-module, per-section regulatory gap assessment for market expansion: for a drug already approved in one market, the platform resolves what a target market requires for that drug type and where those requirements diverge from the original filing — converting a manual, consultant-heavy exercise into a repeatable product capability.
    • — Architected an AI assistant that mines global regulatory updates and auto-drafts submission dossiers for first-in-class device filings, opening a new non-pharma revenue channel.
    • — Direct enterprise data-science and AI product development on Agile, holding delivery to FDA, EMA, and ICH standards across the drug-development lifecycle.
  4. RenaissThera Pvt Ltdnow
    Scientific & AI Advisory Board · Remote
    Sep 2024 – Present
    AI StrategyDrug Discovery
    • — Board-level advisor on AI-driven strategy for early-stage drug discovery and translational research.
    • — Guide regulatory-aware innovation across the company's digital and data-science agenda.
  5. Kstych Pvt Ltd
    Co-Founder | Director, Data Sciences · Gurgaon, India
    Jul 2012 – Aug 2023
    PythonRNLPMongoDBHadoopTableau
    • — Co-founded the firm and built the data-sciences practice from zero — team, methodology, delivery model, and client base.
    • — Advised pharma and biotech leadership on de novo, reformulation, repurposing, and drug-rescue strategy grounded in real-world data.
    • — Built statistical and machine-learning predictive models over RWD using NLP; led therapeutic target assessment and MOA analysis for client programs.
  6. InveniAI LLC
    Senior Director of Data Science · Hybrid Gurgaon IN / CT US
    Sep 2017 – Nov 2020
    PythonAgileData ScienceAI/ML
    • — Set short- and long-term strategy for the data-science and AI organization.
    • — Owned enterprise-scale data-science products end to end across the drug-development lifecycle, delivered on Agile.
    • — Conceptualized and shipped novel solutions spanning discovery through clinical development.
  7. BioXcel Corporation
    Director, Data Sciences | Life Science Consultant · Gurgaon, India
    Nov 2010 – Jul 2017
    Data ScienceDrug RepurposingBig DataStrategy
    • — Directed drug-repurposing and novel-target hypothesis generation using big-data and statistical methods.
    • — Built and mentored the data-science team, owning delivery for US-based pharma and biotech clients.
    • — Advised clients on de novo, reformulation, repurposing, and drug-rescue strategy, plus surveys and future-opportunity mapping using real-world data.
    • — Led strategy consulting and project management, providing the scientific backing for business development.
  8. Ranbaxy
    Research Biologist · Gurgaon, India
    Jan 2008 – Nov 2010
    Molecular BiologysiRNADrug Discovery
    • — Ran siRNA targeted gene silencing for target-based drug discovery.
    • — Cloning, expression, purification, and activity analysis of human kinases, cytochrome P450 proteins, GPCRs, and bacterial enzymes — supporting enzyme- and cell-based NCE screening assays across mammalian, baculovirus, and Dictyostelium expression systems.

Education